#Neladalkib: A Fourth Generation TKI.
#LungCancerTreatment #TargetedTherapies #ALK #TKI
Isabel Preeshagul
#Neladalkib: A Fourth Generation TKI.
#LungCancerTreatment #TargetedTherapies #ALK #TKI
Isabel Preeshagul
Now presenting Dr. Isabel Preeshagul: "ALK, ROS1 and RET Mutations".
Join us at https://give.cancergrace.org/event/lung-cancer-targeted-therapies-onctalk-2026/e759491
ALK receives positive CHMP opinion for EURneffy 1 mg
ALK-Abello has secured a positive recommendation to extend the marketing authorisation for EURneffy. The opinion covers the 1 mg dose, complementing the 2 mg version approved by the EC in August 2024 for anaphylaxis in patients weighing 30 kg or more. EVP of R&D Henriette Mersebach notes this supports the company pediatric focus for respiratory allergy.
El Dr. Daniel Rosas presentando: Nuevas Terapias para Tumores ALK y ROS1 e Indicaciones Adjuvantes.
¿Qué son ALK y ROS1?
#Cáncerdepulmón #ALK #ROS1 #TerapiasDirigidas #Mutacionesdecancerdepulmon #pruebasgenéticas